Bioprocessing & cGMP
In this Issue:
Whether companies have own resources for biologics production or whether contract research organisations do the job: novel molecule formats, cell & gene therapies, more productive cell lines and continous manufacturing challenge their capabilities to innovate and differentiate from the rest of the pack.
- GMP and new processes: Be prepared for hassle
- Interview: Expanding into the commercial space, Franzpeter Bracht, COO, Celonics AG
- Statement: “Learning from the small molecule supply chain”, Rutger Oudejans, Brand Director, UBM
- Biomanufacturing news
You want to be part of European Biotechnology? Get on Board!